New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - levothyroxine sodium, hydrate 111.26ug (pentahydrate equivalent to 100 mcg of anhydrous substance); levothyroxine sodium, hydrate 111.26ug (pentahydrate equivalent to 100 mcg of anhydrous substance) - tablet - 100 mcg - active: levothyroxine sodium, hydrate 111.26ug (pentahydrate equivalent to 100 mcg of anhydrous substance) excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc active: levothyroxine sodium, hydrate 111.26ug (pentahydrate equivalent to 100 mcg of anhydrous substance) excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc - levothyroxine is indicated for the treatment of hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - levothyroxine sodium, hydrate 55.63ug (pentahydrate equivalent to 50 mcg of anhydrous substance) - tablet - 50 mcg - active: levothyroxine sodium, hydrate 55.63ug (pentahydrate equivalent to 50 mcg of anhydrous substance) excipient: colloidal silicon dioxide magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc - levothyroxine is indicated for the treatment of hypothyroidism.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:100000; lidocaine hydrochloride 2%;   - solution for injection - 1:100000/2% in 2.2ml - active: adrenaline acid tartrate 1:100000 lidocaine hydrochloride 2%  

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:200000; bupivacaine hydrochloride monohydrate 0.375%;   - solution for injection - 1:200000/0.375% - active: adrenaline acid tartrate 1:200000 bupivacaine hydrochloride monohydrate 0.375%   excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline acid tartrate 1:200000;  ; bupivacaine hydrochloride monohydrate 0.5%; adrenaline acid tartrate 1:200000; bupivacaine hydrochloride monohydrate 0.5% - solution for injection - 1:200000/0.5% - active: adrenaline acid tartrate 1:200000   bupivacaine hydrochloride monohydrate 0.5% excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection active: adrenaline acid tartrate 1:200000 bupivacaine hydrochloride monohydrate 0.5% excipient: hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite water for injection - marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia · epidural block for surgery. · field block (minor and major nerve blocks and infiltration). analgesia · continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. · field block (minor nerve block and infiltration).

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:200000; bupivacaine hydrochloride monohydrate 0.75%;   - solution for injection - 1:200000/0.75% - active: adrenaline acid tartrate 1:200000 bupivacaine hydrochloride monohydrate 0.75%  

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline acid tartrate 1:400000;  ; bupivacaine hydrochloride monohydrate 0.25%; adrenaline acid tartrate 1:400000; bupivacaine hydrochloride monohydrate 0.25% - solution for injection - 1:400000/0.25% - active: adrenaline acid tartrate 1:400000   bupivacaine hydrochloride monohydrate 0.25% excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection active: adrenaline acid tartrate 1:400000 bupivacaine hydrochloride monohydrate 0.25% excipient: hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite water for injection - marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia · epidural block for surgery. · field block (minor and major nerve blocks and infiltration).

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - haloperidol 5 mg/ml - solution for injection - 5 mg/ml - active: haloperidol 5 mg/ml excipient: lactic acid sodium hydroxide water for injection - the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline acid tartrate 0.018mg equivalent to 10 µg adrenaline;  ; lidocaine hydrochloride monohydrate 10.7mg equivalent to 10 mg lignocaine hydrochloride anhydrous; adrenaline acid tartrate 0.018mg equivalent to 10 µg adrenaline; lidocaine hydrochloride monohydrate 10.7mg equivalent to 10 mg lignocaine hydrochloride anhydrous - solution for injection - active: adrenaline acid tartrate 0.018mg equivalent to 10 µg adrenaline   lidocaine hydrochloride monohydrate 10.7mg equivalent to 10 mg lignocaine hydrochloride anhydrous excipient: hydrochloric acid as 2m solution for ph adjustment (ph 3.3-5.0) methyl hydroxybenzoate sodium chloride sodium hydroxide as 2m solution for ph adjustment (ph 3.3-5.0) sodium metabisulfite water for injection active: adrenaline acid tartrate 0.018mg equivalent to 10 µg adrenaline lidocaine hydrochloride monohydrate 10.7mg equivalent to 10 mg lignocaine hydrochloride anhydrous excipient: hydrochloric acid as 2m solution for ph adjustment nitrogen as nitrogen for injection sodium chloride sodium hydroxide as 2m solution for ph adjustment sodium metabisulfite water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline acid tartrate 0.0091 mg/ml equivalent to 5 µg/ml adrenaline;  ; lidocaine hydrochloride 10 mg/ml; adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]); lidocaine hydrochloride 10 mg/ml; adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]); lidocaine hydrochloride 10 mg/ml - solution for injection - active: adrenaline acid tartrate 0.0091 mg/ml equivalent to 5 µg/ml adrenaline   lidocaine hydrochloride 10 mg/ml excipient: hydrochloric acid as 2m solution for ph adjustment (ph 3.3-5.0) methyl hydroxybenzoate sodium chloride sodium hydroxide as 2m solution for ph adjustment (ph 3.3-5.0) sodium metabisulfite water for injection active: adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]) lidocaine hydrochloride 10 mg/ml excipient: carbon dioxide hydrochloric acid sodium chloride sodium metabisulfite water for injection active: adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]) lidocaine hydrochloride 10 mg/ml excipient: carbon dioxide hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite water for injection - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: · local infiltration · minor or major nerve blocks · epidural block · arthroscopy · intravenous regional anaesthesia